Serial shock severity assessment within seventy-two hours after diagnosis: a cardiogenic shock working group report
Abstract Background The Cardiogenic Shock Working Group-modified Society for Cardiovascular Angiography and Interventions (CSWG-SCAI) staging was developed to risk stratify cardiogenic shock (CS) severity. Data illustrating progressive changes in SCAI stages and outcomes are limited. Purpose We investigated serial changes in CSWG-SCAI stages and outcomes of patients presenting with myocardial infarction- (MI-CS) and heart failure-related (HF-CS) cardiogenic shock. Methods The multi-center CSWG registry was queried. CSWG-SCAI stages were computed at CS diagnosis (baseline, 0 hour) and subsequently at 24, 48, and 72 hours. Results A total of 3268 patients (57% HF-CS, 27% MI-CS) were included. On admission, CSWG-SCAI stage breakdown was: 593 (18.1%) B, 528 (16.2%) C, 1659 (50.8%) D, and 488 (14.9%) non-cardiac arrest stage E (Fig. A). At 24 hours, >50% of stages B and C patients worsened, but 86% of stage D patients stayed at stage D. Among stage E patients, 54% improved to stage D and 36% stayed at stage E by 24 hours. Minimal change in SCAI stages occurred beyond 24 hours. SCAI stage trajectories were similar between MI-CS and HF-CS groups. Notably, stage B patients who worsened to stage C had similar mortality to those remaining at stage C (25.9% vs. 15.8%, p=0.1). Stage B patients worsening to stage D also had similar mortality to stage C patients worsening to stage D (27.4% vs. 25%, p=0.6) (Fig. B). Stage B subjects who remained at stage B by 24 hours still had a 20% in-hospital mortality. Patients who presented in or progressed to stage E by 24 hours had the highest rates of mortality. Conclusions Most patients with CS changed SCAI stages within 24 hours from CS diagnosis. Stage B patients were at high risk of worsening shock severity by 24 hours, associated with excess mortality. Early CS recognition and serial assessment may improve risk stratification.
Authors
- Navin Kumar Kapur (ORCID: https://orcid.org/0000-0002-8302-6796)
- Shelley Hall (ORCID: https://orcid.org/0000-0002-4894-396X)
- Van‐Khue Ton (ORCID: https://orcid.org/0000-0001-8287-2571)
- A.R. Garan (ORCID: https://orcid.org/0000-0001-7510-075X)
- Shashank S. Sinha (ORCID: https://orcid.org/0000-0001-6249-2598)
- Robert L. Goodman (ORCID: https://orcid.org/0000-0003-4080-2596)
- Rachna Kataria (ORCID: https://orcid.org/0000-0001-9065-7687)
- Jaime Hernández-Montfort (ORCID: https://orcid.org/0000-0003-3095-9151)
- Maryjane Farr (ORCID: https://orcid.org/0000-0003-1066-9368)
- Manreet Kanwar (ORCID: https://orcid.org/0000-0002-7280-5268)
- Elric Zweck (ORCID: https://orcid.org/0000-0001-6739-476X)
- Anthony J. Faugno (ORCID: https://orcid.org/0000-0002-1557-4600)
- Bo Li (ORCID: https://orcid.org/0000-0001-7533-4839)
- Song Li (ORCID: https://orcid.org/0000-0002-6427-3986)
- Kevin John
Institutions
- Tufts Medical Center (US)
- Allegheny Health Network (US)
- Harvard University (US)
- Brown University (US)
- Hadassah Medical Center (IL)
- Baylor University Medical Center (US)
- Massachusetts General Hospital (US)
- Düsseldorf University Hospital (DE)
- Alaska Heart and Vascular Institute (US)
- Baylor Scott & White Health (US)
- Heinrich Heine University Düsseldorf (DE)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/eurheartj/ehae666.1184
- Citations
- 1
- Primary Topic
- Acute Myocardial Infarction Research
- Type
- article
- Field-Weighted Citation Impact
- 0.40